Today: 20 March 2026
Subscribe
Browse Category

NYSE:RHHBY 17 July 2025 - 16 September 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····
AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

Roche’s Ventana TROP2 (EPR20043) RxDx test became the first AI-powered diagnostic to receive FDA Breakthrough Device Designation in April 2025. The system uses digital pathology and AI to classify NSCLC tumors as TROP2-positive or negative, guiding use of Datopotamab deruxtecan. In a retrospective analysis, TROP2-positive patients saw a 43% lower risk of progression or death with the drug versus chemotherapy.
17 July 2025
·

Stock Market Today

  • Cintas (CTAS) Share Pullback Prompts Valuation Reassessment Amid Sector Focus
    March 20, 2026, 5:59 AM EDT. Cintas shares have fallen 5.9% over the past week and 6.7% in 30 days, prompting questions about value at the current $181.83 price. Despite a 1.6% year-to-date dip, three-to-five year returns are strong at 72.4% and 125.9%. Investors are scrutinizing pricing, contract quality and cost control in service providers, affecting sector valuations. Cintas scores 0 out of 6 on valuation metrics. A discounted cash flow (DCF) analysis estimates a fair value near $177.18 per share, suggesting shares are about 2.6% overvalued, a margin within typical model error. The company's price-to-earnings (P/E) ratio stands at 38.45x, above the industry average of 22.80x and peer group average of 33.33x, indicating elevated market expectations. Investors should monitor valuation indicators closely given these mixed signals.
Go toTop